Genmab, Seattle expand ADC collaboration with HuMax-CD74

Danish antibody specialist Genmab has reaffirmed the more active partnering strategy instituted last year by new chief executive officer Dr Jan van de Winkel, expanding its research collaboration with Seattle Genetics for antibody-drug conjugates (ADCs) to add a new anticancer candidate to its preclinical pipeline.